|
Amarillo Biosciences is an emerging specialty biopharmaceutical company working in Phase II human clinical trials with interferon alpha, a well-established therapeutic agent.
Our interferon alpha is produced naturally from human cells, not by recombinant technology and is given orally in low doses, making our formulation safer and less expensive.
Amarillo Biosciences is funding clinical trials in the US and working with global partners to conduct other studies around the world to establish the safety and efficacy of low-dose interferon alpha given orally in the treatment or prevention of a number of significant human diseases. |
